RedHill Biopharma’s Opaganib Inhibits COVID-19 Variants in Preclinical Study
RedHill Biopharma Ltd. a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by…
Read More...
Read More...
